JFG
BDTX icon

Jefferies Financial Group’s Black Diamond Therapeutics BDTX Stock Holding History

Jefferies Financial Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.5K Sell
16,208
-5,452
-25% -$13K ﹤0.01% 1660
2025
Q4 		$52.6K Sell
21,660
-1,140
-5% -$4.04K ﹤0.01% 1756
2025
Q3 		$86.4K Buy
+22,800
New +$66.7K ﹤0.01% 1352

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Jefferies Financial Group's BDTX Position: Q1 2026 in Review

Jefferies Financial Group reduced its Black Diamond Therapeutics (BDTX) stake by 25% in Q1 2026, selling an estimated $13K and leaving 16,208 shares worth $34.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Jefferies Financial Group first reported a position in BDTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $86.4K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Jefferies Financial Group held 16,208 shares of Black Diamond Therapeutics worth $34.5K as of Q1 2026.
  • Jefferies Financial Group sold 5,452 Black Diamond Therapeutics shares in Q1 2026, an estimated $13K.
  • Black Diamond Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1660 holding.
  • Jefferies Financial Group first reported a position in Black Diamond Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jefferies Financial Group's Black Diamond Therapeutics position peaked at $86.4K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.